Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Covington
Fuji
QuintilesIMS
Accenture
Chinese Patent Office
Queensland Health
Harvard Business School
Moodys

Generated: April 22, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022421

« Back to Dashboard

NDA 022421 describes MIRAPEX ER, which is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from one supplier. There are two patents protecting this drug and two Paragraph IV challenges. Additional details are available on the MIRAPEX ER profile page.

The generic ingredient in MIRAPEX ER is pramipexole dihydrochloride. There are twenty-four drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the pramipexole dihydrochloride profile page.
Summary for 022421
Tradename:MIRAPEX ER
Applicant:Boehringer Ingelheim
Ingredient:pramipexole dihydrochloride
Patents:2
Formulation / Manufacturing:see details
Pharmacology for NDA: 022421
Mechanism of ActionDopamine Agonists
Suppliers and Packaging for NDA: 022421
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
MIRAPEX ER pramipexole dihydrochloride TABLET, EXTENDED RELEASE;ORAL 022421 NDA Boehringer Ingelheim Pharmaceuticals, Inc. 0597-0109 N 0597-0109-17
MIRAPEX ER pramipexole dihydrochloride TABLET, EXTENDED RELEASE;ORAL 022421 NDA Boehringer Ingelheim Pharmaceuticals, Inc. 0597-0109 N 0597-0109-30

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength0.375MG
Approval Date:Feb 19, 2010TE:ABRLD:Yes
Patent:➤ Sign UpPatent Expiration:Apr 26, 2028Product Flag?YSubstance Flag?Delist Request?
Patent:➤ Sign UpPatent Expiration:Sep 8, 2029Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF PARKINSON'S DISEASE

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength0.75MG
Approval Date:Feb 19, 2010TE:ABRLD:Yes
Patent:➤ Sign UpPatent Expiration:Apr 26, 2028Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 022421

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer Ingelheim MIRAPEX ER pramipexole dihydrochloride TABLET, EXTENDED RELEASE;ORAL 022421-002 Feb 19, 2010 ➤ Sign Up ➤ Sign Up
Boehringer Ingelheim MIRAPEX ER pramipexole dihydrochloride TABLET, EXTENDED RELEASE;ORAL 022421-003 Feb 19, 2010 ➤ Sign Up ➤ Sign Up
Boehringer Ingelheim MIRAPEX ER pramipexole dihydrochloride TABLET, EXTENDED RELEASE;ORAL 022421-001 Feb 19, 2010 ➤ Sign Up ➤ Sign Up
Boehringer Ingelheim MIRAPEX ER pramipexole dihydrochloride TABLET, EXTENDED RELEASE;ORAL 022421-005 Feb 19, 2010 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Covington
AstraZeneca
Express Scripts
Mallinckrodt
Moodys
Queensland Health
Boehringer Ingelheim
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.